ONC

BeOne Medicines Ltd - ADR

BeOne Medicines Ltd. (BeOne) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today launched One Save Changes Everything, a campaign that uses soccer as a lens to recognize the scientific, clinical, and human moments that matter in cancer care. The campaign launches with...

The FDA approved BEQALZI in the treatment of certain mantle cell lymphoma patients on Wednesday.

BeOne Medicines Ltd. (BeOne) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to...

BeOne Medicines (NASDAQ:ONC) reported first-quarter 2026 results that management said reflected "strong execution across the business" and prompted the company to raise its full-year revenue outlook. Co-founder, Chairman and CEO John Oyler said the company entered 2026 with "tremendous momentum," ci...

Wells Fargo & Company upgraded BeOne Medicines to a "strong-buy" rating in a report on Monday...

BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced financial results and corporate updates from the first quarter of 2026. John V. Oyler...

BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC - Get Free Report) has received a consensus rating of "Moderate Buy" from the thirteen analysts that are currently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, two have assigned a ho...

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to a supplemental...

BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will report its first quarter 2026 financial results on Wednesday, May 6, 2026 before the financial markets open. Following the release of the financials, the Company will host a live webcast with management at...